论文部分内容阅读
目的研究协同刺激分子B7同源体1(B7-H1)和B7-H3在乳腺癌组织中的表达及临床意义。方法采用免疫组织化学法检测59例乳腺癌组织及其相应癌旁正常组织中B7-H1、B7-H3表达,并分析其与临床特征的相关性。结果乳腺癌组织中B7-H1和B7-H3阳性表达率分别为47.46%和57.63%,均高于癌旁正常组织(P<0.05)。B7-H1表达与B7-H3表达呈正相关(r=0.917,P<0.01)。乳腺癌组织中B7-H1表达与人类表皮生长因子受体2(Her-2/neu)表达相关(P<0.05),与患者预后无明显相关(P>0.05);而B7-H3表达与患者肿瘤分期及预后均密切相关(P<0.05)。B7-H1/B7-H3双阳性患者5年中位生存率小于B7-H1/B7-H3双阴性患者(61.80%vs.90.10%)(P<0.05)。结论 B7-H1和B7-H3过表达在乳腺癌进展中发挥重要作用,对乳腺癌诊断及预后判断可能具有重要价值。
Objective To study the expression and clinical significance of costimulatory molecules B7 homolog 1 (B7-H1) and B7-H3 in breast cancer. Methods Immunohistochemical method was used to detect the expression of B7-H1 and B7-H3 in 59 cases of breast cancer and corresponding normal tissues. The correlation between them and clinical features was analyzed. Results The positive rates of B7-H1 and B7-H3 in breast cancer tissues were 47.46% and 57.63%, respectively, which were higher than those in normal tissues (P <0.05). B7-H1 expression was positively correlated with B7-H3 expression (r = 0.917, P <0.01). The expression of B7-H1 in breast cancer was correlated with the expression of Her-2 / neu (P <0.05), but not with the prognosis (P> 0.05) Tumor stage and prognosis were closely related (P <0.05). The 5-year median survival rate of B7-H1 / B7-H3 double positive patients was less than that of B7-H1 / B7-H3 double negative patients (61.80% vs.90.10%) (P <0.05). Conclusion Overexpression of B7-H1 and B7-H3 play an important role in the progression of breast cancer and may be of great value in the diagnosis and prognosis of breast cancer.